Current Gastroenterology Reports

, Volume 6, Issue 1, pp 60–65 | Cite as

New concepts of the pathogenesis of alcoholic liver disease lead to novel treatments

  • Charles S. Lieber
Article

Abstract

Activation of methionine to S-adenosylmethionine is depressed in alcoholics. Its repletion opposes alcoholic liver cirrhosis in baboons, decreases mortality in cirrhotic patients, and opposes oxidative stress resulting from cytochrome P4502E1 (CYP2E1) induction by alcohol, ketones, and fatty acids. Their excess causes alcoholic and nonalcoholic steatohepatitis. CYP2E1 is also induced in Kupffer cells, promoting their activation and release of inflammatory cytokines, including tumor necrosis factor (TNF)-α. The TNF-α inhibitor pentoxifylline decreased mortality from alcoholic hepatitis. Polyenylphosphatidylcholine (PPC), an antioxidant phosphatidylcholine mixture extracted from soybeans, 50% of which consists of the highly bioavailable dilinoleoylphosphatidylcholine, restores phospholipids of the damaged membranes and reactivates their enzymes, including phosphatidylethanolamine methyltransferase, needed for phospholipid regeneration. In baboons, PPC prevented cirrhosis by stimulating collagenase and by opposing lipid peroxidation, which produces the fibrogenic hydroxynonenal. PPC was beneficial in patients with alcoholic hepatitis, and it opposed fibrosis in heavy drinkers and decreased aminotransferases in patients with hepatitis C. The antioxidant silymarin also successfully opposed alcoholic cirrhosis in baboons and in some but not all clinical trials; this effect also pertains to α-tocopherol. The anti-inflammatory corticosteroids and colchicine yielded mixed results. Finally, replacing long-chain with medium-chain triglycerides opposed the fatty liver experimentally and clinically.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Raynard B, Balian A, Fallik D, et al.: Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 2002, 35:635–638. Excess weight was found to be a significant risk factor for alcoholic liver disease, including fibrosis, and therefore its correction should be considered in the treatment of alcoholic liver disease.PubMedCrossRefGoogle Scholar
  2. 2.
    Anton RF, Lieber CS, Tabakoff B: Carbohydrate-deficient transferrin and gamma-glutamyltransferase for the detection and monitoring of alcohol use: results from a multisite study. Alcohol Clin Exp Res 2002, 26:1215–1222. This test combination has been validated for the detection of drinking.PubMedGoogle Scholar
  3. 3.
    Volpicelli JR, Alterman AI, Hayashida M, O’Brien CP: Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992, 49:876–880.PubMedGoogle Scholar
  4. 4.
    Lieber CS: Alcoholic liver disease: new insights in pathogenesis lead to new treatments. J Hepatology 2000, 32:113–128.CrossRefGoogle Scholar
  5. 5.
    Duce AM, Ortiz P, Cabrero C, Mato JM: S-adenosyl-L-methionine synthetase and phospholipid methyltransferase are inhibited in human cirrhosis. Hepatology 1988, 8:65–68.PubMedCrossRefGoogle Scholar
  6. 6.
    Lieber CS: Alcoholic liver injury: pathogenesis and therapy in 2001. Pathol Biol 2001, 49:738–752.PubMedCrossRefGoogle Scholar
  7. 7.
    Lieber CS, Casini A, DeCarli LM, et al.: S-adenosyl-L-methionine attenuates alcohol-induced liver injury in the baboon. Hepatology 1990, 11:165–172.PubMedCrossRefGoogle Scholar
  8. 8.
    Frezza M, Surrenti C, Manzillo G, et al.: Oral S-adenosylmethionine in the symptomatic treatment of intrahepatic cholestasis: a double-blind placebo controlled study. Gastroenterology 1990, 99:211–215.PubMedGoogle Scholar
  9. 9.
    Vendemiale G, Altomare E, Trizio T, et al.: Effect of oral S-adenosyl-L-methionine on hepatic glutathione in patients with liver disease. Scand J Gastroenterol 1989, 24:407–415.PubMedGoogle Scholar
  10. 10.
    Mato JM, C’amara J, Fern’andez de Paz J, et al.: S-Adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebocontrolled, double-blind, multicentre clinical trial. J Hepatology 1999, 30:1081–1089. This study reveals that S-adenosylmethionine can decrease the mortality of Child A and B cirrhotics.CrossRefGoogle Scholar
  11. 11.
    Lieber CS: Medical and Nutritional Complications of Alcoholism:Mechanisms and Management. New York: Plenum Press; 1992.Google Scholar
  12. 12.
    Moshage H, Casini A, Lieber CS: Acetaldehyde selectively stimulates collagen production in cultured rat liver fat-storing cells but not in hepatocytes. Hepatology 1990, 12:511–518.PubMedCrossRefGoogle Scholar
  13. 13.
    Ma X, Svegliati-Baroni G, Poniachik J, et al.: Collagen synthesis by liver stellate cells is released from its normal feedback regulation by acetaldehyde-induced modification of the carboxyl-terminal propeptide of procollagen. Alcohol Clin Exp Res 1997, 21:1204–1211.PubMedGoogle Scholar
  14. 14.
    Savolainen E-R, Leo MA, Timpl R, Lieber CS: Acetaldehyde and lactate stimulate collagen synthesis of cultured baboon liver myofibroblasts. Gastroenterology 1984, 87:777–787.PubMedGoogle Scholar
  15. 15.
    Casini A, Cunningham M, Rojkind M, Lieber CS: Acetaldehyde increases procollagen type I and fibronectin gene transcription in cultured rat fat-storing cells through a protein synthesis-dependent mechanism. Hepatology 1991, 13:758–765.PubMedGoogle Scholar
  16. 16.
    Lieber CS: Cytochrome P4502E1: its physiological and pathological role. Physiol Rev 1997, 77:517–544.PubMedGoogle Scholar
  17. 17.
    Lieber CS: Prevention and treatment of liver fibrosis based on pathogenesis. Alcohol Clin Exp Res 1999, 23:944–949.PubMedGoogle Scholar
  18. 18.
    Lieber CS, Robins SJ, Li J, et al.: Phosphatidylcholine protects against fibrosis and cirrhosis in the baboon. Gastroenterology 1994, 106:152–159.PubMedGoogle Scholar
  19. 19.
    Mak KM, Leo MA, Lieber CS: Alcoholic liver injury in baboons: transformation of lipocytes to transitional cells. Gastroenterology 1984, 87:188–200.PubMedGoogle Scholar
  20. 20.
    Mak KI, Lieber CS: Lipocytes and transitional cells in alcoholic liver disease: a morphometric study. Hepatology 1988, 8:1027–1033.PubMedCrossRefGoogle Scholar
  21. 21.
    Poniachik J, Baraona E, Zhao J, Lieber CS: Dilinoleoylphosphatidylcholine decreases hepatic stellate cell activation. J Lab Clin Med 1999, 133:342–348.PubMedCrossRefGoogle Scholar
  22. 22.
    Arai M, Gordon ER, Lieber CS: Decreased cytochrome oxidase activity in hepatic mitochondria after chronic ethanol consumption and the possible role of decreased cytochrome aa3 content and changes in phospholipids. Biochim Biophys Acta 1984, 797:320–327.PubMedGoogle Scholar
  23. 23.
    Navder K, Baraona E, Lieber CS: Polyenylphosphatidylcholine attenuates alcohol-induced fatty liver and hyperlipemia in rats. J Nutr 1997, 127:1800–1806.PubMedGoogle Scholar
  24. 24.
    Lieber CS, Leo MA, Aleynik SI, et al.: Polyenylphosphatidylcholine decreases alcohol-induced oxidative stress in the baboon. Alcohol Clin Exp Res 1997, 21:375–379.PubMedGoogle Scholar
  25. 25.
    Ma X, Zhao J, Lieber CS: Polyenylphosphatidylcholine attenuates non-alcoholic hepatic fibrosis and accelerates its regression. J Hepatology 1996, 24:604–613.CrossRefGoogle Scholar
  26. 26.
    Li J-J, Kim C-I, Leo MA, et al.: Polyunsaturated lecithin prevents acetaldehyde-mediated hepatic collagen accumulation by stimulating collagenase activity in cultured lipocytes. Hepatology 1992, 15:373–381.PubMedCrossRefGoogle Scholar
  27. 27.
    Lieber CS, Robins SJ, Leo MA: Hepatic phosphatidylethanolamine methyltransferase activity is decreased by ethanol and increased by phosphatidylcholine. Alcohol Clin Exp Res 1994, 18:592–595.PubMedCrossRefGoogle Scholar
  28. 28.
    Bird GLA, Panos MZ, Polson R, et al.: Activity of polyunsaturated phosphatidylcholine in HbsAg negative chronic active hepatitis and acute alcoholic hepatitis. Z Gastroenterol 1991, 29:21–24.Google Scholar
  29. 29.
    Niederau C, Strohmeyer G, Heinges T, et al.: Polyunsaturated phosphatidyl-choline and interferon alpha for treatment of chronic hepatitis B and C: a multi-center, randomized, double blind, placebo-controlled trial. Hepatogastroenterology 1998, 45:797–804.PubMedGoogle Scholar
  30. 30.
    Lieber CS, Leo MA, Aleynik SI, et al.: Increasing circulating level of dilinoleoylphosphatidylcholine is associated with protection against alcohol induced oxidative stress and liver fibrosis in man [abstract]. Hepatology 2000, 32:386A.Google Scholar
  31. 31.
    Lieber CS, Weiss DG, Groszmann R, et al.: VA Cooperative study of polyenylphosphatidylcholine in alcoholic liver disease: effects on drinking behavior by nurse/physician teams. Alcohol Clin Exp Res 2003, 27:1757–1764.PubMedCrossRefGoogle Scholar
  32. 32.
    Lieber CS, Weiss DG, Groszmann R, et al.: Cooperative study of polyenylphosphatidylcholine in alcoholic liver disease. Alcohol Clin Exp Res 2003, 27:1765–1772.PubMedCrossRefGoogle Scholar
  33. 33.
    Ferenci P, Dragosics B, Dittrich H, et al.: Randomized controlled trial of silymarin-treatment in patients with cirrhosis of the liver. J Hepatology 1989, 9:105–113.CrossRefGoogle Scholar
  34. 34.
    Pares A, Planas R, Torres M, et al.: Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J Hepatology 1998, 28:615–621.CrossRefGoogle Scholar
  35. 35.
    Lieber CS, Leo MA, Cao Q, et al.: Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons. J Clin Gastroenterol 2003, 37:336–339.PubMedCrossRefGoogle Scholar
  36. 36.
    Leo MA, Rosman A, Lieber CS: Differential depletion of carotenoids and tocopherol in liver diseases. Hepatology 1993, 17:977–986.PubMedGoogle Scholar
  37. 37.
    de la Maza MP, Petermann M, Bunout D, Hirsch S: Effects of long-term vitamin E supplementation in alcoholic cirrhotics. J Am Coll Nutr 1995, 15:192–196.Google Scholar
  38. 38.
    Lieber CS, Lefevre A, Spritz N, et al.: Difference in hepatic metabolism of long and medium-chain fatty acids: the role of fatty acid chain length in the production of the alcoholic fatty liver. J Clin Invest 1967, 46:1451–1460.PubMedGoogle Scholar
  39. 39.
    Nanji AA, Yang EK, Fogt F, et al.: Medium chain triglycerides and vitamin E reduced the severity of established experimental alcoholic liver disease. J Pharmacol Exp Ther 1996, 277:1694–1700.PubMedGoogle Scholar
  40. 40.
    Cabre E, Rodriguez-Iglesias P, Caballeria J, et al.: Short-and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial. Hepatology 2000, 32:36–42.CrossRefPubMedGoogle Scholar
  41. 41.
    Khoruts A, Stahnke L, McClain CJ, et al.: Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients. Hepatology 1991, 13:267–276.PubMedCrossRefGoogle Scholar
  42. 42.
    Sheron N, Bird G, Goka J, et al.: Elevated plasma interleukin-6 and increased severity and mortality in alcoholic hepatitis. Clin Exp Immunology 1991, 84:449–453.Google Scholar
  43. 43.
    Koivisto T, Mishin V, Mak KM, et al.: Induction of cytochrome P-4502E1 by ethanol in rat Kupffer cells. Alcohol Clin Exp Res 1996, 20:207–212.PubMedCrossRefGoogle Scholar
  44. 44.
    Batey R, Cao Q, Madsen G, et al.: Decreased tumor necrosis factor-alpha and interleukin-1alpha production from intrahepatic mononuclear cells in chronic ethanol consumption and up regulation by endotoxin. Alcohol Clin Exp Res 1998, 22:150–156.PubMedGoogle Scholar
  45. 45.
    Akriviadis E, Botla R, Briggs W, et al.: Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind survival in controlled trial. Gastroenterology 2000, 119:1637–1648. This compound is of obvious therapeutic interest in patients with alcoholic hepatitis.PubMedCrossRefGoogle Scholar
  46. 46.
    Jalan R, Williams R, Kaser R: Clinical and cytokine responses to anti-TNF antibody therapy in severe alcoholic hepatitis [abstract]. Hepatology 2001, 34:441A.CrossRefGoogle Scholar
  47. 47.
    Oneta CM, Mak KM, Lieber CS: Dilinoleoylphosphatidylcholine selectively modulates lipopolysaccharide-induced Kupffer cell activation. J Lab Clin Med 1999, 134:466–470.PubMedCrossRefGoogle Scholar
  48. 48.
    Kato J, Sato Y, Inui N, et al.: Ethanol induces transforming growth factor-alpha expression in hepatocytes, leading to stimulation of collagen synthesis by hepatic stellate cells. Alcohol Clin Exp Res 2003, 27:58S-63S.PubMedCrossRefGoogle Scholar
  49. 49.
    Cao Q, Mak KM, Lieber CS: DLPC decreases TGF-beta1-induced collagen mRNA by inhibiting p38 MAPK in hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2002, 283:G1051-G1061.PubMedGoogle Scholar
  50. 50.
    Carithers RL Jr, Herlong FH, Diehl AM, et al.: Methylprednisone therapy in patients with severe alcoholic hepatitis: a randomized multicenter trial. Ann Intern Med 1989, 110:685–690.PubMedGoogle Scholar
  51. 51.
    Ramond MJ, Poynard T, Rueff B: A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med 1992, 326:507–512.PubMedCrossRefGoogle Scholar
  52. 52.
    Christensen E, Gluud C: Glucocorticoids are effective in alcoholic hepatitis: a meta-analysis adjusting for confounding variables. Gut 1995, 37:113–118.PubMedGoogle Scholar
  53. 53.
    Kershenobich D, Vargas F, Garcia-Tsao G, et al.: Colchicine in the treatment of cirrhosis of the liver. N Engl J Med 1988, 318:1709–1713.PubMedCrossRefGoogle Scholar
  54. 54.
    Morgan T, Nemchausky B, Schiff E, et al.: Colchicine does not prolong life in patients with advanced alcoholic cirrhosis: results of a prospective, randomized, placebo-controlled, multicenter VA trial (CSP 352) [abstract]. Gastroenterology 2002, 122:A342.CrossRefGoogle Scholar
  55. 55.
    Aleynik MK, Lieber CS: Dilinoleoylphosphatidylcholine decreases ethanol-induced cytochrome P4502E1. Biochem Biophys Res Commun 2001, 288:1047–1051.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2004

Authors and Affiliations

  • Charles S. Lieber
    • 1
  1. 1.Section of Liver Disease and NutritionBronx VA Medical Center and Mt. Sinai School of MedicineBronxUSA

Personalised recommendations